#USA #Nashville #Teoxane #Revance #RHA Dynamic Volume

Revance and Teoxane Unveil RHA® Dynamic Volume

Revance and Teoxane have recently received FDA approval for their latest injectable, RHA® Dynamic Volume, which aims to enhance midface contours for patients aged 22 and older. Initially known as RHA® 4 Mepi, this innovative product will officially debut under its new name in the first quarter of 2026.

Understanding RHA® Dynamic Volume

The new filler is designed to improve the appearance of the cheeks by correcting age-related volume loss and providing dynamic contour enhancement. Utilizing Preserved Network Technology (PNT), RHA® Dynamic Volume is crafted through a gentle, heat-free crosslinking process that retains the natural structure of hyaluronic acid, ensuring both longevity and structural integrity.

Clinical Trials and Efficacy

The approval follows a 52-week Phase III clinical trial that showcased RHA® Dynamic Volume's effectiveness compared to Juvéderm® Voluma® XC. In this randomized, double-blind study involving multiple centers, results indicated that participants treated with RHA® Dynamic Volume experienced similar outcomes to those using Voluma®, but required fewer treatments and touch-ups. Over 94% of participants reported natural-looking results that felt authentic both at rest and during facial movements, confirming RHA®'s adaptability to dynamic expressions.

Additionally, patients saw marked improvements in cheek attractiveness, youthfulness, smoothness, contour, and symmetry, further solidifying the product's reputation among clinicians and users alike.

In-Depth Treatment Approach

A significant feature of the treatment is the Teoxane MLT (Multilayering Technique™), which targets various tissue depths to provide comprehensive volume restoration. This modern technique allows practitioners to administer RHA® Dynamic Volume into both superficial and deep fat layers according to individual patient anatomy and aging patterns.

The result is a rejuvenated appearance without appearing overdone, fostering a balanced facial harmony. This meticulous approach also emphasizes patient safety by minimizing the risk of injection into high-risk vascular areas.

Expert Insights

Dr. Steven Dayan, a double board-certified facial plastic surgeon, expressed enthusiasm about the introduction of RHA® Dynamic Volume, noting its profound effectiveness in clinical studies. "This advancement not only enhances our ability to meet patient needs but also sets new standards in the aesthetics industry," he commented.

Revance and Teoxane’s Commitment

This approval reflects Revance and Teoxane's ongoing commitment to innovation within the aesthetics domain. Having established themselves as leaders in skincare and aesthetic technologies, both companies are focused on expanding their offerings, which now include a range of high-quality products.

Revance's portfolio also features other notable treatments like DAXXIFY® and SkinPen®, showcasing their dedication to addressing the various needs of patients at every life stage.

Conclusion

As RHA® Dynamic Volume prepares for its market debut in 2026, patients seeking non-surgical solutions for midface contour deficiencies can look forward to a product backed by rigorous clinical evaluation and a significant commitment from its developers. Revance and Teoxane remain at the forefront of aesthetic innovation, ensuring that effective and safe options are available for those seeking to enhance their beauty with confidence. To learn more about their offerings, visit Revance's website.